Crispr Therapeutics Ag Stock Performance
| CRSP Stock | USD 50.84 1.53 3.10% |
Crispr Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.55, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Crispr Therapeutics will likely underperform. Crispr Therapeutics right now shows a risk of 2.9%. Please confirm Crispr Therapeutics potential upside, and the relationship between the total risk alpha and kurtosis , to decide if Crispr Therapeutics will be following its price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Crispr Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 3.1 | Five Day Return 9.64 | Year To Date Return (23.04) | Ten Year Return 260.82 | All Time Return 260.82 |
Last Split Factor 333333:100 | Last Split Date 2016-07-19 |
1 | Disposition of 20000 shares by Samarth Kulkarni of Crispr Therapeutics at 19.12 subject to Rule 16b-3 | 10/04/2024 |
2 | Brokerages Set CRISPR Therapeutics AG Target Price at 75.19 | 10/21/2024 |
3 | Trends in the Plant Breeding And CRISPR Plants Global Market 2024-2033 Emphasis on Genetic and Biological Innovations | 10/30/2024 |
4 | Apellis Q3 Loss Wider Than Expected, Syfovre Drives Revenues YY | 11/06/2024 |
5 | Needham Company LLC Reaffirms Buy Rating for CRISPR Therapeutics | 11/08/2024 |
6 | Intellia shares target cut, maintains outperform on Q3 financials | 11/11/2024 |
7 | Tomatoes could be engineered to be sweeter without sacrificing size, study shows | 11/13/2024 |
8 | CRISPR Therapeutics AG Shares Sold by Bouvel Investment Partners LLC | 11/14/2024 |
9 | CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest | 11/18/2024 |
10 | CRISPR Therapeutics Stock Falls 7 percent in Two Weeks Time to Hold or Sell | 11/20/2024 |
11 | Why Is CRISPR Therapeutics AG Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
12 | Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at... | 11/25/2024 |
| Begin Period Cash Flow | 224.1 M |
Crispr |
Crispr Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,772 in Crispr Therapeutics AG on August 30, 2024 and sell it today you would earn a total of 312.00 from holding Crispr Therapeutics AG or generate 6.54% return on investment over 90 days. Crispr Therapeutics AG is currently generating 0.1399% in daily expected returns and assumes 2.897% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Crispr, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Crispr Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crispr Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crispr Therapeutics AG, and traders can use it to determine the average amount a Crispr Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0483
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CRSP | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.9 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Crispr Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crispr Therapeutics by adding it to a well-diversified portfolio.
Crispr Therapeutics Fundamentals Growth
Crispr Stock prices reflect investors' perceptions of the future prospects and financial health of Crispr Therapeutics, and Crispr Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crispr Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0957 | ||||
| Profit Margin | (1.18) % | ||||
| Operating Margin | (182.94) % | ||||
| Current Valuation | 2.63 B | ||||
| Shares Outstanding | 85.35 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 21.39 X | ||||
| Revenue | 371.21 M | ||||
| Gross Profit | (570.7 M) | ||||
| EBITDA | (202.7 M) | ||||
| Net Income | (153.61 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 238.63 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 22.73 X | ||||
| Cash Flow From Operations | (260.38 M) | ||||
| Earnings Per Share | (2.79) X | ||||
| Market Capitalization | 4.34 B | ||||
| Total Asset | 2.23 B | ||||
| Retained Earnings | (999.7 M) | ||||
| Working Capital | 1.8 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
About Crispr Therapeutics Performance
Assessing Crispr Therapeutics' fundamental ratios provides investors with valuable insights into Crispr Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Crispr Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (42.64) | (40.51) | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.08) | (0.08) |
Things to note about Crispr Therapeutics performance evaluation
Checking the ongoing alerts about Crispr Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crispr Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 371.21 M. Net Loss for the year was (153.61 M) with loss before overhead, payroll, taxes, and interest of (570.7 M). | |
| Crispr Therapeutics AG currently holds about 2.07 B in cash with (260.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.48. | |
| Crispr Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association Scientific Sessions 2024 |
- Analyzing Crispr Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crispr Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Crispr Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crispr Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crispr Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crispr Therapeutics' stock. These opinions can provide insight into Crispr Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.